

BIBLIOGRAPHY

- ดำรงศักดิ์ ฟารุ่งสง. 2546. หลักเภสัชจลนศาสตร์ของยาต้านจุลชีพ สงขลา : ภาควิชาเทคโนโลยีเภสัชกรรม คณะเภสัชศาสตร์ มหาวิทยาลัยสงขลานครินทร์. (Farongsak, 2003).
- Andrew, P. 1988. Perspective in antiinfective therapy. In G.Jackson,H.D.Schlumberger and H.T. Zeiler (eds.). *Proceedings of an International Symposium* (August 31 – September 3), pp. 68-72. Washington D.C. : Vieweg, Braunschweig.
- Anon. 1992. Drugs for treatment of fungal infections. *Med. Lett. Drugs Ther.* 34 : 14-16.
- Anon. 1993. Reports of dangerous cardiac arrhythmias prompt new contraindications for the drug Hismanal. *FDA Med. Bull.* 23(1) : 2-3.
- Backman, JT., Kivistö, KT., Olkkola KT *et al.* 1998. The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. *Eur. J. Clin. Pharmacol.* 54 : 53-8.
- Baker, R.L. and Para, M.F. 1984. Successful use of ketoconazole for invasive cutaneous *Trichophyton rubrum* infection. *Arch. Intern. Med.* 144 : 615-617.
- Balbi, C., D'Ajello, M. and Balbi, G.C. 1986. Treatment with ketoconazole in diabetic Patients with vaginal candidiasis. *Drugs Exp. Clin. Res.* 12 : 413-414.
- Baldwin, S.J., Bloomer, J.C., Smith, G.I., Ayrton A.D. and Clarke S.E., 1995. Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. *Xenobiotica.* 25 : 261-270.

- Barone, J.A., Moskovitz, B.L., Guarnieri, J. *et al.* 1998. Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers. *Pharmacotherapy*. 18 : 295-301.
- Benet, L.Z., Mitchell, J.R. and Sheiner, L.B. 1991. Pharmacokinetic : the dynamics of drug absorption, distribution and elimination. In A.G. *Gilman and L.S. Goodman* (eds.), *Pharmacological Basis of Therapeutics* (8th ed.), pp.3-32. New York : Pergamon Press.
- Benet, L.Z., Kroetz, D.L. and Sheiner, L.B. 1996. Biotransformation of drugs, in Hardman JG, Limbird LL, Molinoff PB, *et al* (eds). *Goodman and Gilman's The Pharmacological Basis of Therapeutics*. (9th ed.), pp.3-28. New York, McGraw-Hill.
- Benet, L.Z., Izumi, T., Zhang, Y., *et al.* 1999. Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. *Journal of Controlled release*. 62 (1-2) : 25-31
- Bennett, W.M., Aronoff, G.R., Golper, T.A. *et al.* 1987. Drug Prescribing in Renal Failure. *American College of Physicians*, Philadelphia, PA,
- Beule, K. D. 1996. Itraconazole: pharmacology, clinical experience and future development. *International Journal of Antimicrobial Agents*. 6 : 175-181.
- Bittencourt, P.R.M., Gracia, C.M., Martins, R. *et al.* 1992. Phenytoin and carbamazepine decrease oral bioavailability of praziquantel. *Neurology*. 42 : 492-496.

- Boelaert, J., Schurgers, M., Matthys, E., *et al.* 1988. Itraconazole pharmacokinetics in patients with renal dysfunction. *Antimicrob Agents Chemother.* 32 : 1595-1597.
- Bohme, A., Ganser, A., and Hoelzer, D. 1995. Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL. *Ann. Hematol.* 71 : 311-312.
- Bosque, E. 2001. Possible drug interaction between itraconazole and vinorelbine tartrate leading to death after one dose of chemotherapy. *Ann. Intern. Med.* 134(5) : 27.
- Brass, C., Galgiani, J.N., Blaschke, T.F., *et al.* 1982. Disposition of ketoconazole, an oral antifungal, in humans. *Antimicrob Agents Chemother.* 21 : 151-158.
- Brown, M.W., Maldonado, A.L., Meredith, C.G. *et al.* 1985. Effect of ketoconazole on hepatic oxidative drug metabolism. *Clin. Pharmacol. Ther.* 37 : 290-297.
- Budavari, S.,ó ., Neil, M.J., Smith, A. and Heckelman, P.E. 1989. *The merck Index.* (11th ed), 1222 pp. U.S.A. : Merck & Co., Inc.
- Bunnag, D. and Harinasuta, T. 1983. Studies of chemotherapy of human opisthorchiasis : III minimum effect dose of praziquantel. *Southeast Asian. J. Trop. Med. Public Health.* 12 : 413-417
- Carlson, J.A., Mann, H.J. and Canafax, D.M. 1983. Effect of pH on disintegration and dissolution of ketoconazole tablets. *Am. J. Hosp. Pharm.* 40 : 1334-1336.

- Cartledge, J.D., Midgely, J., Gazzard, B.G. 1997. Itraconazole solution: higher serum drug concentrations and better clinical response rates than the capsule formulation in acquired immunodeficiency syndrome patients with candidosis. *J. Clin. Pathol.* 50 : 477-80.
- Castro, N., Jung, H., Medina, R., González-Esquivel, D., Lopez, M., Sotelo, J. 2002. Interaction between Grapefruit Juice and Praziquantel in Humans. *Antimicrobial Agents and Chemotherapy.* 46(5) : 1614–1616.
- Castro, N., Medina, R., Sotelo, J. and Jung, H. 2000. Bioavailability of Praziquantel increase with concomitant administration of food. *Antimicrobial Agents and Chemotherapy.* 44(10) : 2903-2904.
- Cauwenbergh, G. 1987. Itraconazole: the first orally active antifungal for single-day treatment of vaginal candidosis. *Curr. Ther. Res.* 41 : 210-214.
- CDC: 1993. Sexually transmitted diseases treatment guidelines. *MMWR.* 42 : 1-99.
- Chambers, H.F. 2001. Antimicrobial agents. *Goodman & Gilman's The Pharmacological Basis of Therapeutics* (10th ed.) pp.1301-1304. New York: McGraw-Hill.
- Cleary, J.D., Taylor, J.W. and Chapman, S.W. 1992. Itraconazole in antifungal therapy. *The Annals of Pharmacotherapy.* 26 : 502-11.
- Como, J.A. and Dismukes, W.E. 1994. Oral azole drugs as systemic antifungal therapy. *New Engl. J. Med.* 330 : 263-272.

- Compendium of Pharmaceuticals and Specialities. Nizoral® Monograph. 1994. 873-5.
- Conti-Diaz, I.A., Civilia, E., Gezuele, E., *et al.* 1992. Treatment of human cutaneous sporotrichosis with itraconazole. *Mycoses*. 35:153-156.
- Correia, M.A. 1998. Drug biotransformation. In B.G. Katzung (ed.), *Basis and Clinical Pharmacology* (7th ed.), pp. 50-61. New Jersey : Prentice Hall International Inc.
- Crane, J.K. and Shih, H. 1993. Syncope and cardiac arrhythmia due to an interaction between itraconazole and terfenadine. *Am. J. Med.* 95 : 445-446.
- Cuce, L.C., Wroclawski, E.L. and Sampaio, S.A.P. 1980. Treatment of paracoccidioidomycosis, candidosis, chromomycosis, lobomycosis, and mycetoma with ketoconazole: a brief summary. *Rev. Infect. Dis.* a; 2 : 650.
- Córdoba-Díaz, D., Córdoba-Díaz, M., Awad, S. and Córdoba-Borrego, M. 2001. Effect of pharmacotechnical design on the in vitro interaction of ketoconazole tablets with non-systemic antacid. *International Journal of Pharmaceutics*. 226 : 61-68.
- Dachman, W.D., Adubofour, K.O., Bikin, D.S., *et al.* 1994. Cimetidine-induced rise in praziquantel levels in a patient with neurocysticercosis being treated with anticonvulsants. *J. Infect. Dis.* 169 : 689-691.
- Daneshmend, T.K., Warnoch, D.W., Enu, M.D., *et al.* 1983. Multiple dose pharmacokinetics of ketoconazole and their effects on antipyrine kinetics in man. *J. Antimicrob. Chemother.* 12 : 185-188.

- Daneshmend, T.K., Warnock, D.W., Ene, M.D., *et al.* 1984. Influence of food on the pharmacokinetics of ketoconazole. *Antimicrob. Agents Chemother.* 25(1) : 1-3.
- de Silva, N., Guyatt, H. and Bundy, D. 1997. Anthelmintic : A comparative review of their clinical pharmacology. *Drugs.* 53(5) : 769-788.
- Degreef, H., Van De Kerckhove, M., Gevers, D., *et al.* 1981. Ketoconazole (R 41 400) in the treatment of dermatophyte infections. *Intl. J. Dermatol.* 20 : 662-669.
- Denning, D.W., Follansbee, S.E., Scolaro, M., *et al.* 1991. Pulmonary Aspergillosis in the acquired immunodeficiency syndrome. *N. Engl. J. Med.* 324 : 654-662.
- Diaz, M., Puente, R., de Hoyos, L.A., *et al.* 1991 Itraconazole in the treatment of coccidioidomycosis. *Chest.* 100 : 682-684.
- Diekmann, H.W., Schneiderei, M. and Overbosch, D. 1989. Inhibitory effects of cimetidine ketoconazole and miconazole on the metabolism of praziquantel. *Acta Leidensia.* 57(2) : 217-228.
- Doherty, M.M. and Charman, W.N. 2002. The Mucosa of the Small Intestine How clinically Relevant as an Organ of Drug Metabolism?. *Clin. Pharmacokinet.* 41 (4) : 235-253.
- Dollery, C. 1999. Itraconazole, Ketoconazole, Quinine. In: *Therapeutic Drugs*. 2nd. vol 2, pp.1120-126, K13-17, London:Hardout brace company limited .
- Edwards, G., and Breckenridge, A.M. 1988. Clinical pharmacokinetics of anthelmintic drugs. *Clin. Pharmacokinet.* 15 : 67-93.

- Eller, M.G. and Okerholm, R.A. 1991. Pharmacokinetic interaction between terfenadine and ketoconazole (abstract). *Clin. Pharmacol. Ther.* 49 : 130.
- Fabris, A., Pellanda, M.V., Gardin, C., *et al.* 1993. Pharmacokinetics of antifungal agents. *Peritoneal Dialysis International.* 13(suppl 2) : S380-2.
- Fallo, P.G., Sturrock R.F., Capron, A., Ninag, M., Docnhoff, M.J. 1995b. Diminished susceptibility to praziquantel in a Senegal isolate of *Schistosoma mansoni*. *Am. J. Trop. Med. Hyg.* 53 : 61-62
- Fauci, A.S., Macher, A.M., Lango, D.L., *et al.* 1984. Acquired immunodeficiency syndrome: epidemiologic, clinical, immunologic, and therapeutic considerations. *Ann. Intern. Med.* 100 : 92-106.
- Fleishaker, J.C., Pearson P.G., Wienkers L.C., *et al.* 1996. Biotransformation of tirilazad in human: 2. Effect of ketoconazole on tirilazad clearance and oral bioavailability. *J. Pharmacol. Exp. Ther.* 227(2) : 991-8.
- Galimberti, R., Negroni, R., Iglesia de Elias, M.R., *et al.* 1980. The activity of ketoconazole in the treatment of onychomycosis. *Rev. Infect. Dis.* 2 : 596-598.
- Gascoigne, E.W., Barton, G.J., Michaels, M., *et al.* 1981. The kinetics of ketoconazole in animal and man. *Clin. Res. (Review)* 1 : 177-187.
- Ghetti, P., Patrone, P. and Tosti, A. 1986. Ketoconazole in the treatment of acne in women (letter). *Arch. Dermatol.* 122 : 629.

- Gibaldi, M. 1991. Compartment and Noncompartment pharmacokinetics. In M. Gibaldi (ed.), *Biopharmaceutics and Clinical Pharmacokinetics* (4th ed.), pp. 14-23. UK, Breckenham: Lea and Febiger Ltd.
- Gibaldi, M. 1992. Drug interactions: part I. *Ann. Pharmacother.* 26 : 709-713.
- Ginsburg, C.M., McCracken, G.H., and Olsen, K. 1983. Pharmacology of ketoconazole suspension in infants and children. *Antimicrob. Agents Chemother.* 23 : 787-789.
- Giorgi, M., Salvatori, A.P., Soldani, G., Giusiani, M., Lungo, V., Gervasi, P.G. and Mengozzi, G. 2001. Pharmacokinetics and microsomal oxidation of praziquantel and its effect on the P450 system in three-month-old lambs infested by *Fasciola hepatica*. *J. vet. Pharmacol. Therap.* 24(4) : 251-259.
- Goldsmith, R.S. 2001. Clinical pharmacology of the anthelmintic drugs. In B.G. Katzung (ed), *Basic and Clinical Pharmacology* (8th ed), pp.903-922. New York: McGraw-Hill.
- Gonzalez, F.J. and Idle, J.R. 1994. Pharmacogenetic phenotyping and genotyping present status and future potential. *Clin. Pharmacokinet.* 26 : 59 – 70.
- Gorski, J.C., Jones, D.R., Haehner-Daniels, B.D., *et al.* 1998. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. *Clin. Pharmacol. Ther.* 64 : 133-143.
- Grant, S.M. and Clissold, S.P. 1989. Itraconazole: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in superficial and systemic mycoses. *Drugs.* 37 : 310-344.

- Graybill, J.R., and Drutz, D.J. 1980. Ketoconazole: a major innovation for treatment of fungal disease. *Ann. Intern. Med.* 93 : 921-923.
- Graybill, J.R., Galgiani, J.N., Jorgensen, J.H., *et al.* 1983. Ketoconazole therapy for fungal urinary tract infections. *J. Urol.* 129 : 68-7042.
- Graybill, J.R., Herndon, J.H., Kniker, W.T., *et al.* 1980. Ketoconazole treatment of chronic mucocutaneous candidiasis. *Arch. Dermatol.* a; 116 : 1137-1141.
- Graybill, J.R., Stevens, D.A., Galgiani, N., *et al.* 1990. Itraconazole treatment of coccidioidomycosis. *Am. J. Med.* 89 : 282-290.
- Greenblatt, D.J., von Moltke, L.L., Harmatz, J.S., *et al.* 1993. Alprazolam pharmacokinetics, metabolism, and plasma levels: clinical implications. *J. Clin. Psychiatry.* 54(suppl 10) : 4-11.
- Greenblatt, D.J., Von Moltke, L.L., Harmatz, J.S., *et al.* 1995. Interaction of triazolam and ketoconazole (letter). *Lancet.* 345 : 191
- Greenblatt, D.J., von Moltke, L.L., Harmatz, J.S., *et al.* 1998. Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole. *Clin. Pharmacol. Ther.* 64 : 661-671.
- Greenblatt, D.J., Wright, C.E., von Moltke, L.L. *et al.* 1998. Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. *Clin. Pharmacol. Ther.* 64 : 237-247.

- Greiner, B., Eichelbaum, M., Fritz, P., *et al.* 1999. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. *J. Clin. Invest.* 104 : 147-153.
- Guengerich, F.P., Brian, W.R., Iwasaki, M. *et al.* 1991. Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 IIIA4. *J. Med Chem.* 34 : 1838-1844.
- Guiniady, M.A., Touny, M.A., Abdel-Bary, M.A., Abdel-Fatah, S.A. and Metwally, A. 1994. Clinical and pharmacokinetic study of praziquantel in Egyptian schistosomiasis patients with and without liver cell failure. *Am. J. Trop. Med. Hyg.* 51(6) : 809-818.
- Halpert, J.R. 1995. Structural basis of selective cytochrome P450 inhibition. *Annual Review of Pharmacology and Toxicology.* 35 : 29-53.
- Hardin, T.C., Graybill, J.R., Fetchick, R., *et al.* 1988. Pharmacokinetics of itraconazole following oral administration to normal volunteers. *Antimicrob. Agents Chemother.* 32 : 1310-1313.
- Hawkins, S.S., Gregory, D.W. and Alford, R.H. 1981. Progressive disseminated histoplasmosis: favorable response to ketoconazole. *Ann. Intern. Med.* 95 : 446-449.
- Hay, R.J. and Clayton, Y.M. 1982. Treatment of chronic dermatophyte infections. The use of ketoconazole in griseofulvin treatment failures. *Clin. Exper. Dermatol.* 7 : 611-617.
- Heel, R.C., Brogden, R.N., Carmine, A., *et al.* 1982. Ketoconazole: a review of its therapeutic efficacy in superficial and systemic fungal infections. *Drugs.* 23 : 1-36.

- Heeres, J., Backx, L.J.J. and Van Cutsen, J. 1984. Antimycotic azoles 7 Synthesis and antifungal properties of series of novel triazole-3 ones. *J. Med. Chem.* 27 : 894-900.
- Herman, B.D., Fleishaker, J.C. and Brow, M.T. 1999. Ketoconazole inhibits the clearance of the enantiomers of antidepressant reboxetine in humans. *Clin. Pharmacol. Ther.* 66(4) : 374-379.
- Hersle, K., Mobergen, H. and Mobergen, S. 1985. Long-term ketoconazole treatment of chronic acral dermatophyte infections. *Int. J. Dermatol.* 24 : 245-248.
- Hickman, J.G. 1996. A double-blind, randomized, placebo-controlled evaluation of short-term treatment with oral itraconazole in patients with tinea versicolor. *J. Am. Acad. Dermatol.* 34 : 785-787.
- Homeida, M., Leahy W., Copeland, S., Ali, M.M.M. and Harron, D.W.G. 1994. Pharmacokinetic interaction between praziquantel and albendazole in Sudanese men. *Trop. Med. Parasitol.* 88(5) : 551-559.
- Honig, P.K., Wortham, D.C., Hull, R. *et al.* 1993. Itraconazole affects single-dose terfenadine pharmacokinetics and cardiac repolarization pharmacodynamics. *J. Clin. Pharmacol.* 33 : 1201-1206.
- Hoppu, K., Tapanainen, P., Tikanoja, T. *et al.* 1991. Accidental astemizole overdose in young children. *Lancet.* 338 : 538-539.

- Hunter, J., Jepson, M.A., Tsuruo, T., Simmons, N.L. and Hirst, B.H. 1993. Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. *J. Biol. Chem.* 268 : 14991-14997.
- Ismail, M., Mctwally, A., Farghaly, A., Brucc, J., Tao, L. and Bennett, J.L. 1996. Characterization of isolates of *Schistosoma mansoni* from Egyptian villagers that tolerate high doses of praziquantel. *Am. J. Trop. Med. Hyg.* 55 : 214-18.
- Jongsuksuntigul, P. and Imsomboon, T. 1998. Epidemiology of opisthorchiasis and national control program in Thailand. *Southeast Asian J. Trop. Med. Public Health.* 29(2) : 327-332.
- Josefsson, M., Zackrisson, A.L. and Ahlner, J. 1996. Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers. *Eur. J. Clin. Pharmacol.* 51 : 189-193.
- Jung, H., Hurtado, M., Sanchez, M., *et al.* 1990. Plasma and CSF levels of albendazole and praziquantel in patients with neurocysticercosis. *Clin. Neuropharmacol.* 13 : 559-564.
- Jung, H., Medina, R., Castro, N. Corona, T. and Sotelo, J. 1997. Pharmacokinetic study of praziquantel administered alone and in combination with cimetidine in a single-day therapeutic regimen. *Antimicrob. Agents Chemother.* 41(6) : 1256-1259.
- Kantola, T., Kivisto, K.T. and Neuvonen, P.J. 1998. Effect of itraconazole on the pharmacokinetics of atorvastatin. *Clin. Pharmacol. Ther.* 64:58-65.

- Kaojarern, S., Nathakarnkikool, S. and Suvanakoot, U. 1989. Comparative bioavailability of praziquantel tablets. *Drug Intell. Clin. Pharm.* 23 : 29-32.
- Karbwang, J., Back, D.J. and Breckenridge, A.M. 1993. Clinical Pharmacology in parasitic diseases. *TROPMED TR.* 150:142-144.
- Kaukonen, K.M., Oikkola, K.T. and Neuvonen, P.J. 1997. Itraconazole increases plasma concentrations of quinidine. *Clin. Pharmacol. Ther.* 62 : 510-517.
- Keogh, A., Spratt, P., McCosker, C., et al. 1995. Ketoconazole to reduce the need for cyclosporine after cardiac transplantation. *N. Engl. J. Med.* 333 : 628-33.
- Khosla, S., Wolfson, J.S., Demerjian, Z. et al. 1989. Adrenal crisis in the setting of high-dose ketoconazole therapy. *Arch. Intern. Med.* 149 : 802-804.
- Kim, R.B., Fromm, M.F., Wandel, C., et al. 1998. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitor. *J. Clin. Invest.* 101 : 289-294.
- King, C.H. and Mahmoud, A.A. 1989. Drugs five years later: praziquantel. *Ann. Intern. Med.* 110 : 290-296.
- Kivisto, K.T., Lamberg, T.S., Kantola, T. et al. 1997. Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole. *Clin. Pharmacol. Ther.* 86 : 348-354.
- Klotz, S.A. and Baartholomew, W.R. 1996. *Candida albicans* keratitis treated successfully with itraconazole. *Cornea.* 15 :102-103.

- Koch, H. 1983. Ketoconazole. *Pharm. Int.* 4 : 151-152.
- Kovacs, G.T., Westcott, M. and Rusden, J. 1990. A prospective study to assess the efficacy of ketoconazole in the treatment of recurrent vaginal candidiasis. *Med. J. Aust.* 153 : 328-330.
- Laurberg, G. 1982. Ketoconazole in trichophyton rubrum. *Acta Dermatovener.* 62 : 273-274.
- Lee, M.W., Kim, J.C., Choi, J.S., *et al.* 1995. Mycetoma caused by *Acremonium falciforme*: successful treatment with itraconazole. *J. Am. Acad. Dermatol.* 32 : 897-900.
- Lefebvre, R.A., Van Peer, A. and Woestenborghs, R. 1997. Influence of itraconazole on the pharmacokinetics and electrocardiographic effects of astemizole. *Br. J. Clin. Pharmacol.* 43 : 319-322.
- Legendre, R. and Steltz, M. 1980. A multi-center, double-blind comparison of ketoconazole and griseofulvin in the treatment of infections due to dermatophytes. *Rev. Infect. Dis.* 2 : 586-591.
- Leopold, G., Ungentum, W., Groll, E., *et al.* 1978. Clinical pharmacology in normal volunteers of praziquantel, a new drug against schistosomes & cestodes. *Eur. J. Clin. Pharmacol.* 14 : 281-291.
- Lerch, C. and Blaschke, G. 1998. Investigation of the stereoselective metabolism of praziquantel after incubation with rat liver microsomes by capillary

electrophoresis and liquid chromatography-mass spectrometry. *Journal of Chromatography B*. 708 : 267-275.

Lin, J.H. and Lu, A.Y.H. 1998. Inhibition and induction of cytochrome P450 and the clinical implications. *Clin. Pharmacokinet.* 35 : 361-390.

Lin, J.L. 2003. Drug-drug interaction mediated by inhibition and induction of P-glycoprotein. *Advanced Drug Delivery Reviews*. 55 : 53-81

Lyman, C.A. and Walsh, T.J. 1992. Systemically administered antifungal agent: a review of their clinical pharmacology and therapeutic application. *Drugs*. 44(1) : 18-34.

Maksymink, A.W., Levine, H.B. and Bodey, G.P. 1982. Pharmacokinetics of ketoconazole in patients with neoplastic diseases. *Antimicrob Agents Chemother.* 22 : 43-46.

Mandell, G.L., Douglas, R.G. and Bennett, J.E. (eds). 1990. *Principles and Practice of Infectious Diseases*, 3rd ed. Churchill Livingstone, New York, NY.

Mandour, M.M., Turabi, H., Homeida, M., Sadig., T., Ali, H., Bennett, J.L., Leahey, W.J. and Harron, D.W.G. 1990. Pharmacokinetics of praziquantel in healthy volunteers and patients with schistosomiasis. *Trans. R. Soc. Trop. Med. Hyg.* 84 : 389-393.

Martinez-Jorda, R., Rodriguez-Sasiain, J.M., Suarez, J.M., *et al.* 1990. Serum binding of ketoconazole in health and disease. *Int. J. Clin. Pharm. Res.* 10 : 271-276.

- Masimirembwa, C.M. and Hasler, J.A. (1994(b)). Characterisation of Praziquantel metabolism by rat liver microsomes using cytochrome P450 inhibitors. *Biochem. Pharmacol.* 48 : 1779-1783.
- Masimirembwa, C.M., Naik, Y.S. and Hasler, J.A. 1994. The effect of chloroquine on the pharmacokinetics and metabolism of praziquantel in rats and in humans. *Biopharm. Drug Dispos.* 15 : 33-43.
- Masimirembwa, C.M., Naik, Y.S. and Hasler, J. A. 1993. Effects of phenobarbital and 3-methylcholanthrene pretreatment on the pharmacokinetics of praziquantel in rat. *Eur. J. Drug Metab. pharmacokinet.* 18 (3) : 261-264.
- Mathews, D.R., McNutt, B., Okerholm, R., *et al.* 1991. Torsades de pointes occurring in association with terfenadine use (letter). *JAMA.* 266 : 2375-2376.
- Mazzu, A., Lasseter, K., Shamblen, E., *et al.* 2000. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. *Clin. Pharmacol. Ther.* 68 : 391-400.
- McGrawth, J. and Murphy, G. M. 1991. The control of seborrhoeic dermatitis and dandruff by antipityrosporal drugs. *Drugs.* 41(2) : 178-184.
- Meier, H. and Blaschke, G. 2000. Capillary electrophoresis-mass spectrometry, liquid chromatography-mass spectrometry and nanoelectrospray-mass spectrometry of praziquantel metabolites. *Journal of Chromatography B.* 748 : 221-231.

- Metwally, A., Bennett, J.L., Botros, S. and Ebeid, F. 1995. Effect of cimetidine, bicarbonate and glucose on the bioavailability of different formulations of praziquantel. *Arzneimittelforschung*. 45(4) : 516-518.
- Meyer, K.C., McManus, E.J. and Maki, D.G. 1993. Overwhelming pulmonary blastomycosis associated with the adult respiratory distress syndrome. *N. Engl. J. Med.* 329 : 1231-1236.
- Mirghani, R.A., Hellgren, U., Westerberg, P.A., *et al.* 1999. The role of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine *in vivo*. *Clin. Pharmacol. Ther.* 66(5) : 454-460.
- Mobacken, H. and Moberg, S. 1986. Ketoconazole treatment of 13 patients with chronic mucocutaneous candidiasis: a prospective 3-year trial. *Dermatologica*. 173 : 229-236.
- Momeni, A.Z., Jalayer, T., Emamjomeh, M., *et al.* 1996. Treatment of cutaneous leishmaniasis with itraconazole: randomized double-blind study. *Arch. Dermatol.* 132 : 784-786.
- Murphy, J.A., Ross, L.M. and Gibson, B.E.S. 1995. Vincristine toxicity in five children with acute lymphoblastic leukaemia (letter). *Lancet*. 346:443.
- Na-Bangchang, K., Karbwang, J., Pungpak, S., Radomyos, B. and Bunnag, D. 1993. Pharmacokinetics of praziquantel in patients with opisthorchiasis. *Southeast Asian J. Trop. Med. Public Health*. 24(4) : 717-723.

- Na-Bangchang, K., Vanijanonta, S. and Karbwang, J. 1995. Plasma concentrations of praziquantel during the therapy of neurocysticercosis with praziquantel in the presence of antiepileptics and dexamethasone. *Southeast Asian J. Trop. Med. Public Health.* 26(1) : 120-123.
- Naranjo, M.S., Trujillo, M., Munera, M.I. *et al.* 1990. Treatment of paracoccidioidomycosis with itraconazole. *J. Med. Vet. Mycol.* 28 : 67-76.
- Negróni, R., Robles, A.M., Arechavala, A., *et al.* 1980. Ketoconazole in the treatment of paracoccidioidomycosis and histoplasmosis. *Rev. Infect. Dis.* 2 : 643-649.
- Neubauer, M.A. and Bodensteiner, D.C. 1992. Disseminated histoplasmosis in patients with AIDS. *South. Med. J.* 85 : 1166-1170.
- Neuvonen, P.J. and Suhonen, R. 1995. Itraconazole interacts with felodipine. *J. Am. Acad. Dermatol.* 33 : 134-135.
- Neuvonen, P.J., Varhe, A. and Olkkola, K.T. 1996. The effect of ingestion time interval on the interaction between itraconazole and triazolam. *Clin. Pharmacol. Ther.* 60 : 326-331.
- Obasi, O.E. and Ozoh, G. 1988. Ketoconazole treatment of dermatomycoses in Kaduna, Nigeria. *Curr. Ther. Res.* 43 : 931-941.
- Ofori-Adjei, D., Adjepon-Yamoah, K. and Lindstrom, B. 1988. Oral praziquantel kinetics in normal and *Schistosoma haematobium*-infected subjects. *Ther. Drug. Monit.* 10 : 45-49.

- Oftebro, H., Jensen, J., Mowinckel, P., *et al.* 1994. Establishing a ketoconazole suppression test for verifying testosterone administration in the doping control of athletes. *J. Clin .Endocrinol. Metab.* 78(4) : 973-977.
- Olkkola, K.T., Ahonen, J. and Neuvonen, P.J. 1996. The effect of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. *Anesth. Analg.* 82 : 511-516.
- Olkkola, K.T., Backman, J.T. and Neuvonen, P.J. 1994. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. *Clin. Pharmacol. Ther.* 55 : 481-485.
- Palkama, V.J., Ahonen, J., Neuvonen, P.J., *et al.* 1999. Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam. *Clin. Pharmacol. Ther.* 66 : 33-9.
- Pappas, P.G., Pottage, J.C., Powderly, W.G., *et al.* 1992. Blastomycosis in patients with the acquired immunodeficiency syndrome. *Ann. Intern. Med.* 116 : 847-853.
- Parija, S.C. and Marrie, T.J. 2002. Trematode Infection. *eMedicine.* 1-11.
- Patterson, T.F., Peters, J., Levine, S.M., *et al.* 1996. Systemic availability of itraconazole in lung transplantation. *Antimicrob Agents Chemother.* 40 : 2217-2220.
- Patzschke, K., Putter, J., Wegner, L.A., *et al.* 1979. Serum concentrations and renal excretion in humans after oral administration of praziquantel - results of three determination methods. *Eur. J. Drug Metab. Pharmacokinet.* 3 : 149-156.

- Pea, F. and Frlanut, M. 2001. Pharmacokinetics aspects of treating infections in the intensive care unit : focus on drug interactions. *Clin. Pharmacokinet.* 40 : 833 – 868.
- Pearson, R.D. and Hewlett, E.L. 1998. Drugs Effective Against Parasitic Infection. *Human Pharmacology Molecular to Clinical* (3rd ed), pp.763-771.
- Pearson, R.L. and Guerrant, R.L. 1983. Praziquantel: a major advance in anthelmintic therapy. *Ann. Intern. Med.* 99 : 195-198.
- Pehrson, P.O., Bengtsson, E., Diekmann, H.W., *et al.* 1983. Treatment with praziquantel in a patient with schistosomiasis and chronic renal failure. *Trans. R. Soc. Trop. Med. Hyg.* 77 : 687-688.
- Pershing, L.K., Corlett, J. and Jorgensen, C. 1994. In vivo pharmacokinetics and pharmacodynamics of topical ketoconazole and miconazole in human stratum corneum. *Antimicrob Agents Chemother.* 38(1) : 90-95.
- Personal Communication: Carmen DeLoria, PharmD, Manager, Department of Professional Services, Janssen Pharmaceutica Inc., Titusville, NJ, March 21, 1995.
- Piscitelli, S.C., Goss, T.F., Wilton, J.H. *et al.* 1991. Effects of ranitidine and sucralfate on ketoconazole bioavailability. *Antimicrob Agents Chemother.* 35(9) : 1765-71.
- Pohjola-Sintonen, S., Viitasalo, M., Toivonen, L., *et al.* 1993. Torsades de pointes after terfenadine-itraconazole interaction. *Br. Med. J.* 306 : 186.

- Poirier, J.M. and Cheymol, G. 1998. Optimisation of itraconazole therapy using target drug concentration. *Clin. Pharmacokinet.* 35(6) : 461-473.
- Polk, R.E., Crouch, M.A., Israel, D.S., *et al.* 1999. Pharmacokinetic interaction between ketoconazole and amprenavir after single doses in healthy men. *Pharmacotherapy.* 19 : 1378-1384.
- Product Information. 1999. Abelcet(R), amphotericin B lipid complex. The Liposome Company, Inc., Princeton, NJ.
- Product Information. 2000. Agenerase(R), amprenavir. Glaxo Wellcome Inc., Research Triangle Park, NC.
- Product Information. 1996. Albenza(R), albendazole tablets. SmithKline Beecham Pharmaceuticals, Philadelphia, PA.
- Product Information. 1998. Hismanal(R), astemizole. Janssen Pharmaceutica Inc., Titusville, NJ.
- Product Information. 2000. Biltricide(R), praziquantel tablets. Bayer corporation, West Haven, CT, (PI revised 10/1996) reviewed 10/2000.
- Product Information. 2000. Lipitor(R), atorvastatin. Parke-Davis, Morris Plains, NJ, (PI revised 03/2000) reviewed 02/2001.
- Product Information. 1995. Nizoral(R) 2% Shampoo. Janssen Pharmaceutica, Titusville, NJ.

Product Information. 2000. Nizoral(R) 2% Shampoo. Janssen Pharmaceutica, Titusville, NJ, (PI revised 8/1997) reviewed 5/2000.

Product Information. 2000. Nizoral(R), ketoconazole tablets. Janssen Pharmaceutica, Titusville, NJ, (PI revised 7/1998) reviewed 2000.

Product Information. 1998. Nizoral(R), ketoconazole. Janssen Pharmaceutica Inc., Titusville, NJ.

Product Information. 1996. Nizoral(R), ketoconazole. Janssen Pharmaceutica Inc., Titusville, NJ.

Product Information. 1995. Nizoral(R), ketoconazole. Janssen Pharmaceutica Inc., Titusville, NJ.

Product Information. 1999. Orap(R), pimozone. Gate Pharmaceuticals, Sellersville, PA.

Product Information. 2000. Propulsid(R), cisapride. Janssen Pharmaceutica Inc., Titusville, NJ.

Product Information. 2001. Sporanox(R) capsules. Janssen Pharmaceutica, Titusville, NJ, (PI revised 04/2001) reviewed 05/2001.

Product Information. 2001. Sporanox(R) injection. Janssen Pharmaceutica, Titusville, NJ, (PI revised 04/2001) reviewed 05/2001.

Product Information. 1997. Sporanox(R), itraconazole. Janssen Pharmaceutica Inc., Titusville, NJ.

- Product Information. 1999. Sporanox(R), itraconazole. Janssen Pharmaceutica Inc., Titusville, NJ.
- Product Information. 2000. Sporanox(R), itraconazole. Janssen Pharmaceutica Inc., Titusville, NJ.
- Product Information. 1997. Versed(R), midazolam. Roche Laboratories Inc., Nutley, NJ.
- Product Information. 1997. Xanax(R), alprazolam. Pharmacia & Upjohn Company, Kalamazoo, MI.
- Queiroz-Telles, F., Purim, K.S., Fillus, J.N., *et al.* 1992. Itraconazole in the treatment of chromoblastomycosis due to *Fonsecaea pedrosoi*. *Int. J. Dermatol.* 31 : 805-812.
- Renton, K.W. 1986. Factors affecting drug biotransformation. *Clin. Biochem.* 19 : 72-75.
- Restrepo, A., Stevens, D.A., Gomez, I., *et al.* 1980. Ketoconazole: a new drug for the treatment of paracoccidioidomycosis. *Rev. Infect. Dis.* 2 : 633-642.
- Riditid, W., Wongnawa, M., Mahathanatrakul, W., Punyo, J. and Sunbhanic, M. 2002. LC determination of praziquantel in human plasma. *J. Pharm. Biomed. Anal.* 28 : 181-186.
- Robertson, M.H., Hanifin, J.M. and Parker, F. 1980. Oral therapy with ketoconazole for dermatophyte infections unresponsive to griseofulvin. *Rev. Infect. Dis.* 2 : 578-581.
- Robertson, M.H., Rich, P., Parker, F., *et al.* 1982. Ketoconazole in griseofulvin-resistant dermatophytosis. *J. Am. Acad. Dermatol.* 6 : 224-229.

- Rosenberg, M.F., Callaghan, R., Ford, R.C. and Higgins, C.F. 1997. Structure of the multidrug resistance P-glycoprotein to 2.5 nm resolution determined by electron microscopy and image analysis. *J. Biol. Chem.* 272 : 10685-10694.
- Rowland, M. and Tozer, T.N. 1995. *Clinical Pharmacokinetics: Concepts and Applications* (3rd Edn ed.), Williams and Wilkins, Baltimore.
- Sanz, F.S. and Hernanz, A.P. 1987. Randomized comparative trial of three regimens of itraconazole for treatment of vaginal mycoses. *Rev. Infect. Dis.* 9(Suppl 1) : S139-S142.
- Schepmann, D. and Blaschke, G. 2001. Isolation and identification of 8-hydroxypraziquantel as a metabolite of the antischistosomal drug praziquantel. *Journal of Pharmaceutical and Biomedical Analysis.* 26 : 791-799.
- Serody, J.S., Mill, M.R., Detterbeck, F.C., *et al.* 1993. Blastomycosis in transplant recipients: report of a case and review. *Clin. Infect. Dis.* 16 : 54-58. 35.
- Sharkey, P.K., Graybill, J.R., Rinaldi, M.G., *et al.* 1990. Itraconazole treatment of phaeohyphomycosis. *J Am Acad Dermatol.* 23 : 577-586.
- Sharkey, P.K., Rinaldi, M.G., Dunn, J.F., *et al.* 1991. High-dose itraconazole in the treatment of severe mycoses. *Antimicrob. Agents Chemother.* 35 : 707-713.
- Sharkey-Mathis, P.K., Kauffman, C.A., Graybill, J.R., *et al.* 1993. Treatment of sporotrichosis with itraconazole. *Am. J. Med.* 95 : 279-285.

- Shulman, R.J. 1996. Cisapride and the attack of the P-450s. *J. Pediatr. Gastroenterol. Nutr.* 23 : 395 - 397.
- Shuster, S. 1984. The etiology of dandruff and mode of action of therapeutic agents. *Br. J. Dermatol.* 111 : 235 - 242.
- Silveira, L.H., Cuellar, M.L., Citera, G., *et al.* 1993. Candida arthritis. *Rheum. Dis. Clin. North. Am.* 19 : 427 -437.
- Silverman, J.A. 2000. P-glycoprotein. In R.H. Levy, *Metabolic Drug Interactions.* pp.135-144. Philadelphia : A Wolters Kluwer.
- Sithithaworn, P., Haswell-Elkins, M.R., Mairiang, P., Satarug, S., Mairiang, E., Vatanasapt, V. 1994. Parasite-associated morbidity: liver fluke infection and bile duct cancer in northeast Thailand. *Int. J. Parasitol.* 24(6) : 833-43
- Slotman, G.J. and Burchard, K.W. 1987. Ketoconazole prevents Candida sepsis in critically ill surgical patients. *Arch. Surg.* 122 : 147-151.
- Smith, A.G. 1984. Potentiation of oral anticoagulants by ketoconazole. *Br. Med. J.* 288 : 188-189.
- Smith, D., Van de Velde, V., Woestenborghs R., *et al.* 1992. The pharmacokinetics of oral Itraconazole in AIDS patients. *J. Pharm. Pharmacol.* 44: 618-9.
- Snook, J., Boothman, B.D., Watkins, J. *et al.* 1988. Torsade de points ventricular tachycardia associated with astemizole overdose. *Br. J. Clin. Pract.* 42 : 257-259.

- Sobel, J.D. 1986. Recurrent vulvovaginal candidiasis: a prospective study of the efficacy of maintenance ketoconazole therapy. *N. Engl. J. Med.* 315 : 1455-1458.
- Sobel, J.D. 1994. Controversial aspects in the management of vulvovaginal candidiasis. *J. Am. Acad. Dermatol.* 31 : S10-S13.
- Sobh, M., El-Agroudy, A., Moustafa, F., *et al.* 1995. Coadministration of ketoconazole to cyclosporin-treated kidney transplant recipients: a prospective randomized study. *Am. J. Nephrol.* 15 : 493-499.
- Sotelo, J. and Jung, H. 1998. Pharmacokinetic optimisation of the treatment of neurocysticercosis. *Clin. Pharmacokinet.* 34(6) : 503-515.
- Spatzenegger, M. and Jaeger, W. 1995. Clinical importance of hepatic cytochrome P450 in drug metabolism. *Drug Metab. Rev.* 27 : 397-417.
- Sugar, A.M., Alsip, S.G., Galgiani, J.N., *et al.* 1987. Pharmacology and toxicity of high-dose ketoconazole. *Antimicrob. Agents Chemother.* 31 : 1874-1878.
- Sugar, A.M., Stern, J.J. and Dupont, B. 1990. Overview: treatment of cryptococcal meningitis. *Rev. Infect. Dis.* 12(Suppl 3) : S338-S348.
- Supanvanich, S., Supanvanich, K. and Pawabut, P. 1982. Field trial of praziquantel in human opisthorchiasis in Thailand. *Southeast Asian. J. Trop. Med. Public Health.* 12 : 598-601.
- Taylor, S., Gupta, A., Walker, S., *et al.* 1996. Peripheral edema due to nifedipine-itraconazole interaction: a case report. *Arch. Dermatol.* 132 : 350-352.

- Talbot, M.D. and Spencer, R.C. 1983. Oral ketoconazole in the treatment of vaginal candidosis. *Curr. Ther. Res.* 34 : 746-749.
- Thummel, K.E., Kunze K.L. and Shen, D.D. 2000. Metabolically-Based Drug-Drug Interactions: Principles and Mechanisms. *Metabolic Drug Interaction.* 3-19.
- Tracy, J.W. and Webster, L.T. 2001. Drugs used in the chemotherapy of helminthiasis. In J.G. Hardman and L.E. Limbird (eds), *Goodman & Gilman's The Pharmacological Basis of Therapeutic* (10th ed) pp.1121-1140. New York: McGraw-Hill.
- Tsunoda, S.M., Velez, R.L., von Moltke, L.L., *et al.* 1999. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. *Clin. Pharmacol. Ther.* 66 : 461-471.
- Tucker, R.M., Denning, D.W., Dupont, B., *et al.* 1990. Itraconazole therapy for chronic coccidioidal meningitis. *Ann Intern Med.* 112 : 108-112.
- Van Cauteren, H., Heykants J., De Coster, R. and Cauwenbergh, G. 1987. Itraconazole: Pharmacologic studies in animals and humans. *Rev. Infect. Dise.* 9(suppl 1) : s43-s46.
- Van Der Meer, J.W.M., Kening, J.J., Scheijrond, H.W., Heykants, J., Van Cutsem, J. *et al.* 1980. Influence of gastric acidity on the bioavailability of ketoconazole. *J. Antimicrob. Chemother.* 6 : 522-524.
- Van Peer, A., Woestenborghs, R., Heykants, J., *et al.* 1989. The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects. *Eur. J. Clin. Pharmacol.* 36 : 423-426.

- Van Tyle, J.H. 1984. Ketoconazole, mechanism of action spectrum of activity pharmacokinetics, drug interactions, adverse reaction and therapeutic use. *Pharmacotherapy*. 4 : 343-373.
- Varhe, A., Olkkola, K.T. and Neuvonen, P.J. 1996. Fluconazole, but not terbinafine, enhances the effects of triazolam by inhibiting its metabolism. *Br. J. Clin. Pharmacol.* 41 : 319-323.
- Varhe, A., Olkkola, K.T. and Neuvonen, P.J. 1994. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. *Clin. Pharmacol. Ther.* 56 : 601-607.
- Vazquez, M.L., Jung, H. and Sotelo, J. 1987. Plasma levels of praziquantel decrease when dexamethasone is given simultaneously. *Neurology*. 37 : 1561-1562.
- Venkatakrishnan, K., Von, L.L. and Greenblatt, D.J. 2000. Effects of the Antifungal Agents on Oxidative Drugs Metabolism. *Clin. Pharmacokinet.* 38(2) : 112-167.
- Vidal-Puig, A.J., Munoz-Torres, M., Jodar-Gimeno, E., et al. 1994. Ketoconazole therapy: hormonal and clinical effects in non-tumoral hyperandrogenism. *Eur. J. Endocrinol.* 130 : 333-338.
- Vivatanasesth, P., Sornmani, S., Schelp, F.P., et al. 1982. Mass treatment of opisthorchiasis in Northeast Thailand. *Southeast Asian. J. Trop. Med. Public Health.* 13 : 609-702.

- Von Moltke, L.L., Greenblatt, D.J., Cotreau-Bibbo, M.M., *et al.* 1994. Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. *Br. J. Clin. Pharmacol.* 38 : 23-31.
- Wacher, V.J., Silverman, J.A., Zhang, Y. and Benet, L.Z. 1998. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. *J. Pharm. Sci.* 87 : 1322-1330.
- Warnock, D.W. 1989. Itraconazole and fluconazole: new drugs for deep fungal infection. *J. Antimicrob. Chemother.* 24 : 275-280.
- Watt, G., White, N.J., Padre, L., *et al.* 1988. Praziquantel pharmacokinetics and side effects in *Schistosoma japonicum*-infected patients with liver disease. *J. Infect. Dis.* 157 : 30-535.
- Wegner, D.H. 1984. The profile of the trematocidal compound praziquantel. *Arzneimittelforschung.* 34 : 1132-1136.
- Welsh, O. and Rodriguez, M. 1980. Treatment of dermatomycoses with ketoconazole. *Rev. Infect. Dis.* 2 : 582-585.
- Wernsdorfer, W. H. and Karbwand, J. 2001. Introduction to Clinical Pharmacology. *Fundamental Clinical Pharmacokinetics* : 1-4. Faculty of Allied Health Sciences.
- Willemsen, M., De Doncker, P., Willems, J., *et al.* 1992. Posttreatment itraconazole levels in the nail. *J. Am. Acad. Dermatol.* 26 : 731-735.

- Winqvist, E.W., Laskey, J., Crump, M., *et al.* 1995. Ketoconazole in the management of paraneoplastic Cushing's syndrome secondary to ectopic adrenocorticotropin production. *J. Clin. Oncol.* 13(1) : 157-164.
- Wishart, J.M. 1987. The influence of food on the pharmacokinetics of itraconazole in patients with superficial fungal infection. *J. Am. Acad. Dermatol.* 17 : 220-223.
- Wispelwey, b. and Neu, H. C. 1998. Antifungal Agents. *Human Pharmacology Molecular to Clinical* (3rd ed). 735-744.
- Zhang, Y. and Benet, L.Z. 2001. The Gut as a Barrier to Drug Absorption Combined Role of Cytochrome P450 3A and P-glycoprotein. *Clin. Pharmacokinet.* 40(3) : 159-168.
- Zhang, Y.J. and Guan, Y.Z. 1997. Involvement of cytochrome P4503A in the monohydroxylation of ring A of praziquantel in rat liver microsomes. *Yao Xue Xue Bao.* 32 (1) : 5 – 10.